0 items

in your cart
$0.00

  • Search for Medications
  • Viewcart | Checkout
  • Manage Account
  •  
  • Click-to-Call  

Prescription Drug Search

Strengths available for Rimonabant :

Search for a drug:

 

Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about GlobalPharmacyMeds.to

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Rimonabant:

  • Albania
  • Anguilla
  • Austria
  • Bangladesh
  • Barbados
  • Bosnia and Herzegovina
  • Cayman Islands
  • Czech Republic
  • Gibraltar
  • Greenland
  • Honduras
  • Hungary
  • India
  • Indonesia
  • Iran
  • Jamaica
  • Japan
  • Lebanon
  • Liechtenstein
  • Luxembourg
  • Malta
  • Morocco
  • Netherlands
  • New Zealand
  • Panama
  • Paraguay
  • Peru
  • Qatar
  • Russian Federation
  • Saint Lucia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Trinidad and Tobago
  • Tunisia
  • United Arab Emirates
  • United Kingdom, UK
  • United States, US
  • Yemen
View All Countries

Latest news releases on Rimonabant:

Rimonabant - Wikipedia

Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn ...

Acomplia: Uses, Dosage, Side Effects & Warnings - Drugs.com

Sanofi-Aventis has withdrawn rimonabant from the market globally and it is no longer under development. 1 Acomplia was officially withdrawn by the European Medicines ...

Rimonabant - an overview | ScienceDirect Topics

Atrial fibrillation has been attributed to rimonabant in two cases [114 A]. • A man who took rimonabant for 5 weeks developed palpitation, fatigue, and exertional ...

Rimonabant | C22H21Cl3N4O - PubChem - The PubChem Project

Rimonabant is a pyrazole and piperidine derivative that acts as a selective cannabinoid type-1 receptor (CB1 RECEPTOR) antagonist. It inhibits the proliferation and ...

European Medicines Agency - - Acomplia

European Union agency responsible for the protection of public and animal health through the scientific evaluation and supervision of medicines.

Acomplia (Rimonabant) - Investigational Agent for the ...

Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. It works...Read More...

Rimonabant — Wikipédia

Le rimonabant (ou SR141716) est un médicament anorexigène contre l'obésité agissant comme un agoniste inverse des récepteurs cannabinoïdes CB1.

Rimonabant - Wikipedia, la enciclopedia libre

Rimonabant (conocido también como SR141716), [n 1] es un inhibidor del apetito que actualmente se encuentra fuera del mercado en gran parte del mundo.

Rimonabant – Wikipedia

Rimonabant ist ein Arzneistoff, der als Appetitzügler zur Behandlung des Übergewichts eingesetzt wurde, eigentlich allerdings zur Raucherentwöhnung von dem ...

The psychiatric side-effects of rimonabant.

RESULTS: Clinical trials have revealed that rimonabant may promote weight loss in obese patients, although it may also induce symptoms of anxiety and depression.

Customer Service
1-866-799-3435 (Use ref# 10786) | Contact Form
Copyright © 2019 GlobalPharmacyMeds.to All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK